AD

- . .

Award Number: DAMD17-02-1-0122

TITLE: IGF-Regulated Genes in Prostate Cancer

PRINCIPAL INVESTIGATOR: Charles T. Roberts, Jr., Ph.D.

CONTRACTING ORGANIZATION: Oregon Health Science University Portland, Oregon 97201-3098

REPORT DATE: February 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030702 061

Philication by based the isolation of biomedia is assets in to compare any operating the source of the isolation of the	REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Average and set days. Repeate Network Set 000-000. View Mathematic 2000. 3. REPORT TYPE AND DATES COVERED. 1. AGRECU USE ONLY (Laws Hank) 2. REPORT ATE 3. REPORT TYPE AND DATES COVERED. 4. TITLE AND SUBTITLE 2. REPORT ATE 5. FORMOR NUMBERS 1GF - Regulated Genes in Prostate Cancer 5. FORMOR NUMBERS 6. AUTHOR(S): Charles T. Roberts, Jr., Ph.D. 8. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Oregon Health Science University Portland, Oregon 97201-3098 8. PERFORMING ORGANIZATION F.Mas: robercs@chau.edu 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 11. SUPPLEMENTARY NOTES 11. SUPPLEMENTARY NOTES 12. DISTRIBUTION / AVAILABLITY STATEMENT Approved for Public Release; Distribution Unlimited 12. DISTRIBUTION CODE 12. DISTRIBUTION CODE 13. Abstrate Maximum 200 Woodd (distinct should contain no proprieting or confidential information) 12. DISTRIBUTION CODE 14. SUMPLEMENTARY NOTES 12. DISTRIBUTION / AVAILABLITY STATEMENT 12. DISTRIBUTION CODE 13. Abstrate Maximum 200 Woodd (distinct should c	the data needed, and completing and reviewing	this collection of information. Send comments rega	rding this burden estimate or any ot	her aspect of this coll	ection of information, including suggestions for
4. TITLE AND SUBTIVE 5. FUNDING NUMBERS IGF-Regulated Genes in Prostate Cancer 5. AUTHORISI: Charles T. Roberts, Jr., Ph.D. 8. AUTHORISI: Charles T. Roberts, Jr., Ph.D. 8. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Oregon Health Science University 8. PERFORMING ORGANIZATION Portland, Oregon 97201-3098 8. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 11. SUPPLEMENTARY NOTES 12b. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release, Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract Maximum 200 Words/ (abstract should contain no proprietary or confidential information) 12b. DISTRIBUTION CODE 14. SUPPLEMENTARY NOTES 12b. DISTRIBUTION CODE 12b. DISTRIBUTION CODE 15. Abstract Maximum 200 Words/ (abstract should contain no proprietary or confidential information) 12b. DISTRIBUTION CODE 16 differentially expressed genes and periodus in Maxemic Information) 12b. DISTRIBUTION CODE 16 differentially expressed genes and periodus in Maxemic Control of the probesis, we proposed there specific autis on dynamic har ac differentially requestion in chervis sisgenes	Management and Budget, Paperwork Reduction	Project (0704-0188), Washington, DC 20503	· · · · · · · · · · · · · · · · · · ·		
IGF-Regulated Genes in Prostate Cancer DAMD17-02-1-0122 6. AUTHORISI: Charles T. Roberts, Jr., Ph.D. 8. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REFORT NUMBER Oregon Health Science University Portland, Oregon 97201-3098 8. PERFORMING ORGANIZATION REFORT NUMBER 8. PERFORMING ORGANIZATION REFORT NUMBER US. Anny Medical Reserch and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSORING / MONITORING AGENCY REFORT NUMBER 13. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract Machine 200 Work/ (Matrix: Junual Constitute valuable diagnostic markers or theraptic target genes may include metastasic prosting of the egnes and are under progression and are used EDL-10F mars speciment to its protections that are differential speciment to specime cancer progression and have used EDL-10F and speciment to its protections that are differential speciment to its contains are produced to the cell line and in an 1, and 3). Assessment of the differential capression of these genes and gene products in lase-microdisceted samples. We have used microgravy gene produce the specific minity operated genes and have used EDL-10F and speciment to its differential species in the cell line and in an 1, and 3). Assessment of the differential capression of these genes and gene products in lase-microdisceted samples. We have used microgravy gene produce the internation of these genes and gene products in lase-microdisceted samples. We have used microgravy gene produce the internation of these genes and gene products in lase-microdisceted samples. We have used microgravy gene produce the int		February 2003	Annual (1 Feb	and the second se	
Charles T. Roberts, Jr., Ph.D. 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Oregon Health Science University Portland, Oregon 97201-3098 E-Maik roberts@ohsu.edu 5. SFONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. Abstract (Maximum 200 Wordd) (abstract should contain no proprietury or confidential information) We hypothesized that genes that are differentially expressed as a result of the decreased IGF-1 receptor gene expression seen in metastatic prostate cancer progression. IGF-1 receptor target genes may include metastatic ry. non-metastatic prostate cancer proteins that are differentially regulated in otherwise isogenic metastatic vs. non-metastatic prostate cancer proteins that are differentially regulated in otherwise isogenic metastatic vs. non-metastatic prostate cancer contribute to prostate cancer progression. IGF-1 receptor target genes may include metastatic vs. non-metastatic prostate cancer contribute of genes and gene products in last-microdissected samples. We have used microarray gene profiling to characterize differentiall expressed genes and gene products in last-amicrodissected samples. We have used in aim 1, and 3) Assessment of the differential expression of these genes and gene products in last-amicrodissected samples. We have used increarray gene profiling to characterize differentially expressed genes and gene products in Bast-microdissected samples. We have used in aim 1, and 3) Assessment of the di		s in Prostate Cance	r		
Oregon Health Science University Portland, Oregon 97201-3098 REPORT NUMBER E-Mail: robertsc@ohsu.edu 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSORING / MONITORING AGENCY REPORT NUMBER 11. SUPPLEMENTARY NOTES 12b. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) 12b. DISTRIBUTION CODE 14. SUBJECT TERMINE value diagnostic markers or thrapeutic targets. To evalue this hypothesis, we proposed three specific inits: 1) Identification of proteins that are differentially secreted in the cell lines used in aim 1, and 3) Assessment of the differential expression of these genes and have used SELDI-TOF mass spectrometry to identify proteins that are differentially secreted in the cell lines used in aim 1, and 3) Assessment or the characterize differentially expressed genes and have used SELDI-TOF mass spectrometry to identify proteins that are differentially secreted in the cell lines used in aim 1, and 3) Assessment of the characterize differentially expressed genes and have used SELDI-TOF mass spectrometry to identify proteins that are differentially secreted in the collines of the set of the differential types in a microgramy and SELDI-TOF analyses in 3-D culture before proceeding to the validation of differential expressio	· ·	, Jr., Ph.D.			
Oregon Health Science University Portland, Oregon 97201-3098 Image: Control of the second	7. PERFORMING ORGANIZATION	NAME(S) AND ADDRESS(ES)		8. PERFORMI	NG ORGANIZATION
Portland, Oregon 97201-3098 E-Mail: robertsc@ohsu.edu 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESSIES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) We hypothesized that genes that are differentially expressed as a result of the decreased IGF-I receptor gene expression seen in metastatic prostate cancer contribute to prostate cancer progression. IGF-I receptor agene expression seen in metastatic prostate cancer contribute to prostate cancer progression. IGF-I receptor gene may include metastasis-promoting or suppressing genes that could constitute valuable diagnostic markers or threapeutic targets. To evaluate this hypothesize three specific aims: 1) Identification of genes that are differentially equipted in otherwise isogenic metastatic vs. non-metastatic prostate epithelial cells; 2) Identification of proteins that are differentially secreted in the cell lines used in atin 1, and 3) Assessment of the differential expression of these genes and have used SELDI-TOF mass spectrometry to identify proteins that are differentially secreted into conditioned media. We have additionally initiated a 3-dimensional culture system to grow prostate cells in a microgravity environment that more accurately replicates in vivo cell organization and phenotype. We are now preparing to quickly repeat our microarray and SELDI-TOF analyses in 3-D culture before proceeding to the validation of differential expression in clinical samples using prostate tissue arrays. 14. SUBJ	Oregon Health Science University			REPORT NUMBER	
3. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSORING / MONITORING AGENCY REPORT NUMBER 11. SUPPLEMENTARY NOTES 11. SUPPLEMENTARY NOTES 12b. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) 12b. DISTRIBUTION code We hypothesized that genes that are differentially expressed as a result of the decreased IGF-1 receptor gene expression seen in metastatic prostate conditioned or proteins that are differentially regulated in otherwise isogenic metastatic is non-metastatic prostate cold constitute valuable diagnostic markers or therapeutic targets. To evaluate this hypothesis, we proposed three specific aims: 1) Identification of proteins that are differentially regulated in otherwise isogenic metastatic vs. non-metastatic prostate collicial cells; 2) Identification of proteins that are differentially secreted into coll lines used in an 1, and 3) Assessment of the differential expression of these genes and gene products in laser-microdissected samples. We have used microarray gene profiling to characterize differentially explicases in vivo cell organization and phenotype. We are now preparing to quickly repeat our microarray and SELDI-TOF malyses in 3-D culture before proceeding to the validation of differential expression in clinical samples using prostate tissue arrays. 14. SUBJECT TERMS: insul1n-1ike growth factor, gene profiling, protein profiling 15. NUMBER OF PAGES					
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 AGENCY REPORT NUMBER 11. SUPPLEMENTARY NOTES 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract <i>Maximum 200 Words</i> / <i>(abstract should contain no proprietary or confidential information)</i> 12b. DISTRIBUTION CODE We hypothesized that genes that are differentially expressed as a result of the decreased IGF-I receptor gene expression seen in metastatic prostate cancer contribute to postate cancer progression. IGF-1 receptor target genes may include metastasis-promoting or suppressing genes that could constitute valuable diagnostic markers or therapeutic targets. To evaluate this hypothesis, we proposed three specific aims: 1) I dentification of proteins that are differentially regulated in otherwise isogenic metastatic vs. non-metastatic prostate epithelial cells; 2) Identification of proteins that are differentially secreted in the cell lines used in aim 1, and 3) Assessment of the differential expression of these genes and have used SELDI-TOF mass spectrometry to identify proteins that are differentially secreted into conditioned media. We have additionally initiated a 3-dimensional culture system to grow prostate cells in a microgravity environment that more accurately replicates in vivo cell organization and phenotype. We are now preparing to quickly repeat our incroarray and SELDI-TOF analyses in 3-D culture before proceeding to the validation of differential expression in clinical samples using prostate tissue arrays. 16. NUMBER OF PAGES 10. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE Unclassified 19. SECURITY CLASSIFICATION OF THIS	E-Mail: robertsc@ohsu.edu				
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 AGENCY REPORT NUMBER 11. SUPPLEMENTARY NOTES 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract <i>Maximum 200 Words</i> / <i>(abstract should contain no proprietary or confidential information)</i> 12b. DISTRIBUTION CODE We hypothesized that genes that are differentially expressed as a result of the decreased IGF-I receptor gene expression seen in metastatic prostate cancer contribute to postate cancer progression. IGF-1 receptor target genes may include metastasis-promoting or suppressing genes that could constitute valuable diagnostic markers or therapeutic targets. To evaluate this hypothesis, we proposed three specific aims: 1) I dentification of proteins that are differentially regulated in otherwise isogenic metastatic vs. non-metastatic prostate epithelial cells; 2) Identification of proteins that are differentially secreted in the cell lines used in aim 1, and 3) Assessment of the differential expression of these genes and have used SELDI-TOF mass spectrometry to identify proteins that are differentially secreted into conditioned media. We have additionally initiated a 3-dimensional culture system to grow prostate cells in a microgravity environment that more accurately replicates in vivo cell organization and phenotype. We are now preparing to quickly repeat our incroarray and SELDI-TOF analyses in 3-D culture before proceeding to the validation of differential expression in clinical samples using prostate tissue arrays. 16. NUMBER OF PAGES 10. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE Unclassified 19. SECURITY CLASSIFICATION OF THIS	9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)			10. SPONSOR	ING / MONITORING
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) 12b. DISTRIBUTION CODE 14. Augmentation of genes that are differentially expressed as a result of the decreased IGF-I receptor gene expression seen in metastatic prostate cancer contribute valuable diagnostic markers or therapeutic targets. To evaluate this hypothesis, we proposed three specific aims: 1) Identification of genes that are differentially secreted in the cell lines used in aim 1, and 3) Assessment of the differential expression of these genes and gene products in laser-microdissected samples. We have used microarray gene profiling to characterize differentially expressed genes and have used SELDI-TOF mass spectrometry to identify proteins that are differentially secreted in the cell lines used in aim 1, and 3) Assessment of the differential differentially expressed genes and have used SELDI-TOF mass spectrometry to identify proteins that are differentially secreted into conditioned media. We have additionally initiated a 3-dimensional culture system to grow prostate cells in a microgravity environment that more accurately replicates in vivo cell organization and phenotype. We are now preparing to quickly repeat our microarray and SELDI-TOF analyses in 3-D culture before proceeding to the validation of differential expression in clinical samples using prostate tissue arrays. 14. SUBJECT TERMS: 15. NUMBER OF PAGES insulin-like growth factor, gene profiling, protein profiling 15. NUMBER OF PA	U.S. Army Medical Research and Materiel Command			AGENCY REPORT NUMBER	
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) 12b. DISTRIBUTION CODE 14. Augmentation of genes that are differentially expressed as a result of the decreased IGF-I receptor gene expression seen in metastatic prostate cancer contribute valuable diagnostic markers or therapeutic targets. To evaluate this hypothesis, we proposed three specific aims: 1) Identification of genes that are differentially secreted in the cell lines used in aim 1, and 3) Assessment of the differential expression of these genes and gene products in laser-microdissected samples. We have used microarray gene profiling to characterize differentially expressed genes and have used SELDI-TOF mass spectrometry to identify proteins that are differentially secreted in the cell lines used in aim 1, and 3) Assessment of the differential differentially expressed genes and have used SELDI-TOF mass spectrometry to identify proteins that are differentially secreted into conditioned media. We have additionally initiated a 3-dimensional culture system to grow prostate cells in a microgravity environment that more accurately replicates in vivo cell organization and phenotype. We are now preparing to quickly repeat our microarray and SELDI-TOF analyses in 3-D culture before proceeding to the validation of differential expression in clinical samples using prostate tissue arrays. 14. SUBJECT TERMS: 15. NUMBER OF PAGES insulin-like growth factor, gene profiling, protein profiling 15. NUMBER OF PA					
We hypothesized that genes that are differentially expressed as a result of the decreased IGF-I receptor gene expression seen in metastatic prostate cancer contribute to prostate cancer progression. IGF-I receptor target genes may include metastasis-promoting or suppressing genes that could constitute valuable diagnostic markers or therapeutic targets. To evaluate this hypothesis, we proposed three specific aims: 1) Identification of genes that are differentially regulated in otherwise isogenic metastatic vs. non-metastatic prostate epithelial cells; 2) Identification of proteins that are differentially secreted in the cell lines used in aim 1, and 3) Assessment of the differential expression of these genes and gene products in laser-microdissected samples. We have used microarray gene profiling to characterize differentially expressed genes and have used SELDI-TOF mass spectrometry to identify proteins that are differentially secreted into conditioned media. We have additionally initiated a 3-dimensional culture system to grow prostate cells in a microgravity environment that more accurately replicates in vivo cell organization and phenotype. We are now preparing to quickly repeat our microarray and SELDI-TOF analyses in 3-D culture before proceeding to the validation of differential expression in clinical samples using prostate tissue arrays. 14. SUBJECT TERMS: 15. NUMBER OF PAGES insulin-like growth factor, gene profiling, protein profiling 15. NUMBER OF PAGES 6 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 0F REPORT 0F THIS PAGE 0C ABSTRACT 0r. Lassified Unclassified Unlimited <td< td=""><td></td><td></td><td>limited</td><td></td><td>12b. DISTRIBUTION CODE</td></td<>			limited		12b. DISTRIBUTION CODE
insulin-like growth factor, gene profiling, protein profiling 17. SECURITY CLASSIFICATION OF REPORT Unclassified NSN 7540-01-280-5500 Insulin-like growth factor, gene profiling, protein profiling 18. SECURITY CLASSIFICATION OF ABSTRACT Unclassified OF ABSTRACT Unclassified Unclassifi	We hypothesized that genes the metastatic prostate cancer contri- suppressing genes that could co- three specific aims: 1) Identific prostate epithelial cells; 2) Ident the differential expression of the to characterize differentially exp secreted into conditioned media. environment that more accurate microarray and SELDI-TOF and	at are differentially expressed as bute to prostate cancer progressio nstitute valuable diagnostic marked cation of genes that are different ification of proteins that are differ esse genes and gene products in las pressed genes and have used SELI We have additionally initiated a ly replicates in vivo cell organiza	a result of the decrea n. IGF-I receptor target ers or therapeutic target ially regulated in othe entially secreted in the er-microdissected samp DI-TOF mass spectrom 3-dimensional culture st ation and phenotype.	sed IGF-I rec et genes may in rs. To evaluat rwise isogenic cell lines used les. We have etry to identify ystem to grow We are now p	nclude metastasis-promoting or e this hypothesis, we proposed e metastatic vs. non-metastatic in aim 1, and 3) Assessment of used microarray gene profiling proteins that are differentially prostate cells in a microgravity oreparing to quickly repeat our
16. PRICE CODE 17. SECURITY CLASSIFICATION OF REPORT 18. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 20. LIMITATION OF ABSTRACT Unclassified Unclassified Unclassified Unlimited NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89)					
OF REPORT UnclassifiedOF THIS PAGE UnclassifiedOF ABSTRACT UnclassifiedUnlimitedNSN 7540-01-280-5500UnclassifiedUnlimitedStandard Form 298 (Rev. 2-89)			3		
UnclassifiedUnclassifiedUnlimitedNSN 7540-01-280-5500Standard Form 298 (Rev. 2-89)					20. LIMITATION OF ABSTRACT
NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89)				led	Unlimited
	NSN 7540-01-280-5500				ndard Form 298 (Rev. 2-89)

•

v

Table of Contents

• • •

.

Co	over1	
SF	F 2982	
Introduction	······	4
Bo	ody4	
Key Research	h Accomplishments	5
Reportable O	Dutcomes	5
Conclusions		5
References		5
Appendices		6

Introduction:

.

The insulin-like growth factor (IGF) signaling system plays an important role in the initation and progression of prostate cancer. High circulating levels of IGF-I are associated with an increased risk of developing prostate cancer, and constitutive expression of IGF-I in the prostate epithelium of transgenic mice results in neoplasia. The actions of IGF-I are mediated through activation of the IGF-I receptor, a transmembrane tyrosine kinase that is highly expressed in normal prostate epithelium and immortalized prostate epithelial cell lines. A significant decrease in IGF-I receptor expression is seen in metastatic prostate cancer cell lines, human metastases, and metastatic lesions from transgenic mouse models of prostate cancer. Retroviral re-expression of the IGF-I receptor in metastatic prostate cancer cells reduces their tumorigenicity and metastatic potential. These data suggest that, while IGF-I action may contribute to the initiation of prostate cancer, a subsequent loss of IGF responsiveness secondary to reduced IGF-I receptor expression is necessary for progression to advanced disease. This requirement for decreased IGF-I responsiveness may reflect the ability of the activated IGF-I receptor to exert differentiative as well as proliferative effects. Our hypothesis is that genes that are differentially expressed as a result of the decreased IGF-I receptor gene expression seen in metastatic prostate cancer contribute to prostate cancer progression. Specifically, IGF-I receptor target genes may include metastasis-promoting or suppressing genes that could constitute valuable diagnostic markers or therapeutic targets. To evaluate this hypothesis, we proposed three specific aims: 1) Identification of a select subset of genes that are differentially regulated in otherwise isogenic metastatic vs. non-metastatic prostate epithelial cells that differ solely in the level of expression of the IGF-I receptor; 2) Identification of proteins that are differentially secreted in the cell lines used in aim 1, and 3) Assessment of the differential expression of these genes and gene products in laser-microdissected samples from normal prostate, adenocarcinoma, and metastatic lesions. The studies of specific aim 1 employ microarray gene profiling of metastatic prostate epithelial cells and their non-metastatic counterparts that are re-expressing the IGF-I receptor from a retroviral construct. The studies of aim 2 employ surface-enhanced laser desorption-ionization/time-of-flight (SELDI-TOF) mass spectroscopy to identify proteins that are differentially present in the conditioned media of the two cell types utilized in aim 1. Subsequent tandem mass spectroscopy analyses will be performed to generate proteolylic cleavage patterns or peptide sequences for gene identification. The studies of specific aim 3 will evaluate the expression of IGF-I receptor target genes in a series of human clinical samples using quantitative real-time RT-PCR analyses. The proposed studies address a critical aspect of prostate cancer, i.e., factors that contribute to the development of advanced disease. The studies underway employ an innovative, integrated, gene and protein profiling approach in a novel, carefully defined and highly controlled model system to identify genes and gene products that regulate metastasis.

Body:

The approved statement of work included three tasks that were to be initiated in the first 12 months of funding. These tasks were in support of aims 1 and 2 of the proposed project. These will be discussed in turn.

Task 1:Completion of microarray analysis of genes differentially expressed in LISN and LNLG cells that express different levels of IGF-I receptor and which are, respectively, non-metastatic and metastatic in nude mouse xenografts. We have completed this analysis using three independent RNA preparations from each cell line grown in defined medium with 1% FBS and have analyzed each sample using triplicate arrays that each contain >12,000 sequence-verified, non-redundant human cDNA clones. Data have been analyzed by accepted means of normalization, statistical verification and false-discovery rate analyses. These data demonstrate that there are specific genes that are constantly differentially expressed in LISN and LNLG cells. We have recently acquired a rotary cell culture system for three-dimensional (3-D) cultures of cells in a microgravity environment. This NASA-designed apparatus had been used to propagate cells under conditions that alter them to form 3-D structures that may be more similar to the in vivo situation (1,2). Indeed, a recent report has shown that tumor cell lines grown under microgravity conditions display a phenotype that is much more similar to that of clinical samples in situ than cells grown in monolayer cultures (3). This system has been used in several previous studies to grow prostate cells in particular (4-7). We would like to propose to use this novel culture

system to repeat the array analysis that constituted task 1, since we feel that the data obtained will be significantly more relevant than that obtained with standard monolayer culture.

Task 2:Completion of preliminary SELDI-TOF analysis of conditioned media from M12-LISN and M12-LNLG cultures. We have completed several profiles using normal phase protein array chips in the Ciphergen PBSII SELDI-TOF platform, and have identified a number of molecular weight species that appear to be differentially expressed and secreted by the two cell lines. For further investigation however, we would prefer to generate additional profiles of cells grown in 3-D cultures, for the reasons cited above for task 1. This will be a relatively simple change to implement, since we can easily obtain RNA and conditional media from the same rotary cultures.

Task 3:Generation of probes for Northern and/or RPA analysis and verification of differential gene expression in M12-LISN and M12-LNL6 cells. We have begun to design primers of generation of cDNA probes for some of the robustly differentially expressed genes identified in the array studies of task 1, but will first determine which of these are differentially expressed in these cell lines grown in 3-D culture before proceeding further.

Tasks 4-8, slated for performances in years 2 and 3, remain largely unaltered, except that through our collaborator, Dr. Stephen Plymate, we will now have access to prostate tissue arrays containing over 100 samples ranging from normal prostate epithelium through Gleason grade 9 tumors. This will facilitate the analysis of differential expression of target genes for which suitable antibodies are available, and will be preferable to analyzing individual specimens on separate slides, since all the samples on the tissue array are processed simultaneously.

Key research accomplishments:

- Demonstration of differential gene expression profiles in M12-LISN and M12-LNLG cells expressing different levels of IGF-I receptor.
- > Demonstration of differential secreted protein expression in M12-LISN and M12-LNLG cells.
- Establishment of 3-D cell culture system for M12-LISN and M12-LNLG cell culture.

Reportable outcomes: None for this funding period.

Conclusions: We have shown that differences in IGF-I receptor gene expression that are sufficient to alter metstatic capacity are sufficient to alter gene expression and secreted protein expression profiles in monolayer cell culture. There is an increasing appreciation that findings made in monolayer cell culture may not accurately reflect the molecular situation in vivo, as compared to what can be achieved with 3-D culture approaches (3, 8-10). We are, however, well positioned to quickly reevaluate differential gene and secreted protein expression in 3-D culture, which will allow us to then proceed with the additional components of the statement of work using more promising candidate IGF-regulated genes.

References:

1. Hammond, TG, and Hammond, JM. Am J Physiol Renal Physiol 281, F12 (2001).

2. Unsworth BR and Lelkes PI, Nature Medicine 4, 901 (1998).

3. Nakamura K, Kuga H, Morisaki T, Baba E, Sato N, Mizumoto K, Sueshi K, Tanaka M and Katano M, *Biotechniques* **33**, 1068 (2002).

4. O'Connor KC, *Pharmaceutical Research* 16, 486 (1999).

5. Rhee H, Chang S, Garner T and Chung L, J Urology 159, (Suppl) 5 (1998).

6. Clejan S, O'Connor K and Rosenweig N, J Cell Mol Med 5, 60 (2001).

7. Rhee, HW, Shau, HE, Pathak, S, Multani, AS, Oennanen, S, Visakorpi, T, and Chung, LWK, *In Vitro Cell Dev Biol Anim* 37, 127 (2001).

8. Jacks T and Weinberg RA: Taking the Study of Cancer Cell Survival to a New Dimension. *Cell* 111, 923 (2002).

9. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, and Brugge JS, Cell 111, 29 (2002).

10. Weaver VM, Lelievre S, Lakins JN, Chrenek MA, Jones JCR, Giancotti F, Werb Z, and Bissell MJ, *Cancer Cell* 2, 205 (2002).

Appendices: None.